While diabetes has long been associated with retinal disease, vascular dysfunction, and chronic ocular inflammation, its potential relationship with anterior uveitis has received far less attention.
Earlier research has suggested that poor glycemic control may increase inflammatory eye disease risk in diabetic patients, raising questions about whether chronic hyperglycemia directly contributes to anterior segment inflammation.
With this in mind: Researchers behind a new multicenter cohort study published in Eye explored that possibility using more than 12 million patient records from the TriNetX database.
Their findings suggest the risk of undifferentiated anterior uveitis rises progressively alongside worsening HbA1c levels in diabetic patients.
Why are researchers even looking at this possible connection?
Diabetes is already known to affect multiple ocular tissues through chronic vascular dysfunction, oxidative stress, and inflammatory signaling.
Researchers have increasingly questioned whether those same mechanisms may also influence the anterior segment and contribute to inflammatory eye disease.
In the current study, the authors proposed a possible mechanism as well:
- Chronic hyperglycemia may weaken the blood-aqueous barrier
- Increase vascular permeability
- Promote intraocular cytokine production
Together, those changes could potentially create a more inflammation-prone intraocular environment.
So how did this study actually evaluate the risk?
Researchers conducted a retrospective multicenter cohort study using data from the TriNetX database, a large federated research network containing de-identified electronic health record (EHR) data from healthcare systems across multiple institutions.
The analysis included adult patients between 2010 and 2023 and ultimately evaluated data from 12,192,033 individuals aged 18+.
Importantly, investigators excluded patients with:
- Pre-existing uveitis
- Systemic inflammatory diseases
- Conditions already known to independently increase inflammatory risk
That allowed the researchers to focus more specifically on incident undifferentiated anterior uveitis in relation to glycemic control itself.
How were the patient groups divided?
Investigators created three exposure groups based on diabetes status and HbA1c levels:
- Poorly controlled diabetes (HbA1c ≥8.0%)
- Well-controlled diabetes (HbA1c <8.0%)
- Non-diabetic controls
And based on that?
Of the total study population:
- 12.7% fell into the poorly controlled diabetes group
- 20.8% had well-controlled diabetes
- 66.5% were non-diabetic controls
The study also included patients across multiple racial and demographic groups, including White, Black, Hispanic, and “other race” categories.
What did the researchers find?
The overall trend was fairly clear: Worsening glycemic control was associated with higher uveitis risk.
Compared with non-diabetic controls:
- Patients with well-controlled diabetes had an adjusted hazard ratio (aHR) of 3.25
- Patients with poorly controlled diabetes had an aHR of 4.07
Researchers found that for every 1% increase in HbA1c, the odds of developing anterior uveitis increased by roughly 10%.
In other words: Risk appeared to increase in step with worsening glycemic control rather than simply being tied to diabetes diagnosis alone.
Does this mean all anterior uveitis patients should now be screened for diabetes?
Interestingly, the authors specifically stated that the findings do not support routine laboratory screening for every patient presenting with new-onset undifferentiated anterior uveitis.
Their reasoning: Poorly controlled glycemia was still identified in fewer than one in five uveitis cases overall.
Instead, the researchers suggested a more targeted approach:
- Testing patients with known diabetes
- Evaluating individuals with limited routine medical care
- Considering glycemic screening in otherwise unexplained cases
Essentially, the findings support selective metabolic evaluation rather than universal screening protocols.
Were there any limitations?
Like most retrospective database studies, this one comes with important limitations.
First: Diagnoses relied on electronic health record coding and documentation accuracy across multiple healthcare systems, which introduces some variability.
Second: The study focused specifically on undifferentiated anterior uveitis, meaning the findings may not necessarily apply to all uveitis subtypes.
And while the researchers adjusted for multiple confounding variables, observational data cannot establish direct causation.
- The study demonstrated association, but it could not definitively prove that worsening glycemic control directly causes uveitis.
The authors also acknowledged that additional non-quantifiable inflammatory or systemic factors may influence risk in diabetic populations.
So why are these findings getting attention in eye care?
Because they potentially expand the conversation around diabetes-related eye disease beyond the retina.
Clinicians already strongly associate diabetes with:
- Diabetic retinopathy
- Diabetic macular edema
- Retinal vascular complications overall
But this study suggests poor glycemic control may also influence anterior segment inflammatory disease risk in a measurable way.
… meaning … ?
From a clinical standpoint, that could eventually affect:
- How eye care providers approach unexplained anterior uveitis
- How systemic metabolic health factors into inflammatory workups
- How interdisciplinary care evolves between ophthalmology, endocrinology, and primary care
At the same time, the authors were careful not to overstate the findings. Additional prospective studies will still be needed to clarify mechanism, causality, and long-term clinical implications.
And now, the take home.
This study found that patients with uncontrolled diabetes faced a significantly higher risk of undifferentiated anterior uveitis, with risk increasing along with HbA1c levels.
While the findings do not support universal diabetes screening in all uveitis patients, they do strengthen the growing connection between systemic metabolic health and ocular inflammatory disease.